Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 1, 1997, Pages 16-22

  Serebruany, Victor L ^a,e   Ordonez, Jose V ^b   Herzog, William R ^b   Rohde, Morten ^c   Mortensen, Svend A ^c   Folkers, Karl ^d   Gurbel, Paul A ^a  

^a Heart Assoc Res and Educ Found   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e UNION MEMORIAL HOSPITAL   (United States)

Author keywords

Antioxidants; Coenzyme Q10; Flow cytometry; Human; Platelets; Ubiquinone; Vitronectin receptor

Indexed keywords

UBIDECARENONE; VITRONECTIN;

ADULT; ARTICLE; CELL SIZE; DIET SUPPLEMENTATION; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; ISCHEMIA; NORMAL HUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REPERFUSION INJURY; THROMBOCYTE MEMBRANE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BLOOD PLATELETS; FEMALE; FLOW CYTOMETRY; FOOD, FORTIFIED; HUMANS; INTEGRIN ALPHAV; INTEGRIN BETA3; MALE; PARTICLE SIZE; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, VITRONECTIN; UBIQUINONE;

EID: 0031012474     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199701000-00003     Document Type: Article

References (42)

1. Battino M, Fato R, Lenaz G. Coenzyme Q10 can control the efficiency of oxidative phosphorylation. Int J Tissue React 1990;12: 137-44.
2. Beyer RE. The participation of coenzyme Q10 in free radical production and antioxidation. Free Radic Biol Med 1990;8:545-65.
3. Lenaz G, Battino M. Studies on the role of ubiquinone in the control of the mitochondrial respiratory chain. Free Radic Res Commun 1990;8:317-27.
4. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci USA 1985;82: 901-4.
5. Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (Ubiquinone). Clin Invest 1993;71:5116-23.
6. Greenberg SM, Frishman WH. Coenzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990;30:596-608.
7. Atar D, Mortensen SA, Flachs H, Herzog WR. Coenzyme Q10 protects ischemic myocardium in an open-chest swine model. Clin Invest 1993;71:5103-11.
8. Wu KK, Philips M, D'Souza D, Hellums JD. Platelet activation and arterial thrombosis. Lancet 1994;344:991-8.
9. Schor K, Braun M. Platelets as a source of vasoactive mediators. Stroke 1990;21(suppl IV):32-5.
10. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. FASEB J 1995;9:866-73.
11. Patel KD, Zimmerman GA, Prescott SM, McEver RP, McIntyre TM. Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils. J Cell Biol 1991;112:749-59.
12. Koerner TA, Cunningham MT, Zhang DS. The role of membrane lipid in the platelet storage lesion. Blood Cells 1992;18:481-97.
13. Herzog WR, Schlossberg ML, Mortensen SA, Serebruany VL. Dietary supplementation with coenzyme Q10 reduces platelet aggregability in swine. Coenzyme Q Res Biol Med 1995;3:5-8.
14. Ault KA. Flow cytometric measurement of platelet function and reticulated platelets. Ann N Y Acad Sci 1993;677:293-308.
15. Faraday N, Goldschmidt-Clermont P, Dise K, Bray PF. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med 1994;123:728-40.
16. Giles H, Smith RE, Martin JF. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest 1994;24:69-72.
17. Kario K, Matsuo T, Nakao K. Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis. Clin Lab Haematol 1992;14:281-7.
18. Tschoepe D, Roesen P, Esser J, et al. Large platelets circulate in an active state in diabetes mellitus. Semin Thromb Hemost 1991;17: 433-8.
19. Edlund PO. Determination of coenzyme Q10, alpha-tocopherol and cholesterol in biological samples by coupled-column liquid chromatography with colorimetric and ultraviolet detection. J Chromatogr 1988;425:87-97.
20. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995;1271: 195-204.
21. Salonen JT, Salonen R, Seppanen K, et al. Effects of antioxidant supplementation on platelet function. Am J Nutrition 1990;53:1222-9.
22. Bierenbaum ML, Reichstein RP, Bragavan HN, Watkins TR. Relationship between serum lipid peroxidation products in hypercholesterolemic subjects and vitamin E status. Biochem Int 1992;28: 57-66.
23. Salonen JT. Antioxidants and platelets. Ann Med 1989;21:59-62.
24. Rao GH, Tate MR, Murthy M, Hebbel RP, White JG. Influence of antioxidants on arachidonic acid metabolism and platelet function. Biochem Med Metab Biol 1994;51:74-9.
25. Serebruany VL, Herzog WR, Atamas SP, et al. Hemostatic changes after dietary coenzyme Q10 supplementation in swine. J Cardiovasc Pharmacol 1996;28:175-81.
26. Folkers K, Moore HW Lenaz G, Szarkowska L. Organic structural specificity of coenzyme Q for biological activity. Biochem Biophys Res Commun 1966;23:386-91.
27. Skelton S, Folkers K. Biosynthesis of ubiquinone-10 from p-hydroxybenzoic acid by leukocytes of the human and rhesus monkey. J Intern Vit 1970;40:153-8.
28. O'Malley S, Langhorne P, Elton RA, Stewart C. Platelet size in stroke patients. Stroke 1995;26:995-9.
29. Smyth DW, Martin JF, Michalis L, Bucknall CA, Jewitt DE. Influence of platelet size before coronary angioplasty of subsequent restenosis. Eur J Clin Invest 1993;23:361-7.
30. Halbmayer W-M, Haushofer A, Radek J, Schon R, Deutsch M, Fisher M. Platelet size, fibrinogen and lipoprotein(a) in coronary artery disease. Coron Artery Dis 1995;6:397-402.
31. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. FASEB J 1995;9:866-73.
32. Preissner KT. Structure and biological role of vitronectin. Annu Rev Cell Biol 1991;7:275-310.
33. Clyman RI, McDonald KA, Kramer RH. Integrin receptors on aortic smooth muscle cells mediate adhesion to fibronectin, laminin and collagen. Circ Res 1990;67:175-86.
34. Satoh T, Kouns WC, Yamashita Y, Kamiyama T, Steiner B. Tetrafibricin has a high selectivity for GP IIb/IIIa: comparison of the effects of tetrafibricin and RGDS on GP IIb/IIIa and the vitronectin receptor. Biochem Biophys Res Commun 1994;204:325-32.
35. Nip J, Rabbani SA, Shibata HR, Brodt P. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest 1995;95: 2096-103.
36. Brown SL, Lundgren CH, Nordt T, Fujii S. Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. Cardiovasc Res 1994;28:1815-20.
37. Murphy JF, Bordet JC, Wyler B, et al. The vitronectin receptor (alpha v beta 3) is implicated in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cells. Biochem J 1994;304:537-42.
38. Seiffert D, Ciambrone G, Wagner NV, Binder BR, Loskutoff DJ. The somatomedin B domain of vitronectin - structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem 1994;269:2659-66.
39. Wci Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994;269:32380-8.
40. Coller BS, Cheresh DA, Asch E, Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood 1991;77:75-83.
41. Roger M, Halstensen TS, Hogasen K, Mollnes TE, Solum NO, Hovig T. Platelets and vitronectin: immunocytochemical localization and platelet interaction with exogenously added vitronectin. Nouv Rev Fr Hematol 1992;34:47-54.
42. Beacham DA, Cryz MA, Handin RI. Glycoprotein Ib can mediate endothelial cell attachment to a von Willebrand factor substratum. Thromb Haemost 1995;73:309-17.